A patient on Latuda (lurasidone) develops akathisia; how should it be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Latuda-Induced Akathisia

When a patient on Latuda (lurasidone) develops akathisia, the first-line approach is to reduce the lurasidone dose while staying within the therapeutic range (40-80 mg/day), or add propranolol 10-30 mg two to three times daily. 1

Initial Assessment and Diagnosis

  • Confirm true akathisia by identifying both subjective inner restlessness and objective motor restlessness (inability to sit still, pacing, compulsion to move), as akathisia is frequently misinterpreted as psychotic agitation or anxiety, which can lead to inappropriate dose increases that worsen the condition. 1, 2

  • Recognize that lurasidone carries a notable akathisia risk, with akathisia being one of the most commonly encountered adverse events alongside somnolence, nausea, and parkinsonism. 3, 4, 5

  • Be aware that even low introductory doses can precipitate severe akathisia, as documented in case reports where patients developed distressing symptoms that resolved completely upon discontinuation. 2

Step-by-Step Management Algorithm

Step 1: Dose Reduction

  • Reduce lurasidone to 40 mg/day (the recommended starting dose) if the patient is on a higher dose, as this may alleviate akathisia while maintaining therapeutic efficacy. 1, 3

  • Note that the number needed to harm (NNH) for akathisia varies by dose, with 120 mg/day showing NNH of 6, while lower doses may be better tolerated. 5, 6

Step 2: Add Propranolol (First-Line Pharmacological Treatment)

  • Initiate propranolol at 10-30 mg two to three times daily, as this is the most consistently effective treatment for akathisia according to psychiatric guidelines. 1

  • Propranolol should be considered before other adjunctive agents due to its superior evidence base. 1

Step 3: Consider Benzodiazepines (Second-Line)

  • Add clonazepam or lorazepam if propranolol is contraindicated or ineffective, as benzodiazepines can provide symptomatic relief and address the anxiety component of akathisia. 1

  • Use benzodiazepines cautiously and for short-term stabilization only. 1

Step 4: Anticholinergic Agents (Less Effective but May Try)

  • Benztropine 1-4 mg once or twice daily may be attempted, though anticholinergic agents are notably less effective for akathisia compared to other extrapyramidal side effects. 1

  • Monitor carefully for anticholinergic side effects, particularly in vulnerable populations. 1

Step 5: Switch Antipsychotics

  • If dose reduction and adjunctive treatments fail, switch to quetiapine or olanzapine, which have lower akathisia risk profiles. 1, 4

  • Perform gradual cross-titration considering each medication's half-life and receptor profile to preserve therapeutic effect while minimizing akathisia recurrence. 1

  • For olanzapine, consider concurrent use with samidorphan or metformin to mitigate weight gain. 1

Critical Pitfalls to Avoid

  • Never increase the lurasidone dose when akathisia presents, as this common error stems from misinterpreting akathisia as worsening psychosis or anxiety. 1, 2

  • Do not routinely prescribe prophylactic anticholinergic agents, as they are less effective for akathisia and increase anticholinergic burden unnecessarily. 1

  • Screen for suicidality if akathisia develops, particularly in patients with treatment-resistant depression, as akathisia is associated with increased suicidal ideation. 1

Dose-Specific Considerations

  • The 160 mg/day dose appears better tolerated for akathisia than 40-120 mg/day doses, with no statistically significant NNH values for akathisia at this dose versus placebo. 5

  • However, doses of 80-120 mg carry the highest risk for akathisia, nausea, somnolence, and extrapyramidal symptoms, requiring prompt dose adjustment if these adverse reactions worsen. 6

Monitoring and Follow-Up

  • Document abnormal movements at baseline and repeat assessments every 3-6 months using the Abnormal Involuntary Movement Scale, as up to 50% of patients on antipsychotics develop movement disorders. 1

  • Most side effects with lurasidone are transitory and easily managed with dose adjustment, but akathisia requires active intervention rather than watchful waiting. 4

Related Questions

I switched from aripiprazole (Abilify) to lurasidone (Latuda) for akathisia but still have tremor; how should I manage this?
Can lurasidone cause nausea?
What are the next steps for patients who can tolerate lurasidone (latuda) 20 mg?
Should a switch to Lurasidone be considered for a patient with a history of psychosis, autism, insomnia, and ADHD, who has gained significant weight on Abilify (aripiprazole)?
What is the best course of action for a 36 year old female patient taking lurasidone (latuda) 40mg for bipolar schizophrenia who complains of mood swings?
What are the contraindications to ipratropium bromide nasal spray?
When should an indwelling Foley catheter be changed?
In an adult patient taking trazodone 100 mg at bedtime who falls asleep but awakens about three hours later, what short‑acting hypnotic can be added for sleep‑maintenance insomnia?
What is the appropriate treatment for a 15‑year‑old girl with streptococcal tonsillitis, including first‑line antibiotic regimen and alternatives for penicillin allergy?
What is the appropriate workup and differential diagnosis for a young to middle‑aged adult with severe anxiety and intermittent left‑sided sharp chest pain, given a normal chest radiograph, normal comprehensive metabolic panel, normal complete blood count, normal twelve‑lead electrocardiogram, and normal D‑dimer assay?
For a patient with atrial fibrillation taking rivaroxaban (Xarelto), should the medication be discontinued before a carpal tunnel release?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.